Imophoron was a preclinical biotechnology company developing ADDomer, a self-assembling, thermostable protein nanoparticle platform, to combat infectious diseases.
The development risk was that Imophoron was a pre-clinical stage company built around a novel next generation nanoparticle vaccine platform called ADDomer. Its proof of concept data for two highly infectious diseases demonstrated potential to prevent disease and transmission.
A £4 million investment was intended to bring ADDomer vaccines to clinical stage, initially targeting RSV, COVID-19 and mosquito-borne Chikungunya. An announced process development partnership with eXmoor Pharma included a future GMP manufacturing route. Imophoron dissolved on 16 December 2025.
2Product Overview
ADDomer's design combined a patented self-assembling protein scaffold with thermostability so that a single particle carried many epitopes. The technology created highly immunogenic vaccine candidates on a multimeric protein-based nanoparticle scaffold. It enabled rapid design with nanoparticles carrying 180 epitopes.
ADDomer vaccines were thermostable and could be stored and transported at room temperature, while conventional vaccines required refrigeration. Imophoron intended to deliver its vaccines intranasally as an over-the-counter nasal spray alternative to injections for common viruses such as the flu.